Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 9/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 6/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 6/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 6/20 | 1.00 |
| ▸ | TSHR | P16473 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | GABRP | O00591 | 1/20 | 1.00 |
| ▸ | GABRD | O14764 | 1/20 | 1.00 |
| ▸ | GABRA1 | P14867 | 1/20 | 1.00 |
| ▸ | GABRB1 | P18505 | 1/20 | 1.00 |
| ▸ | GABRG2 | P18507 | 1/20 | 1.00 |
| ▸ | GABRB3 | P28472 | 1/20 | 1.00 |
| ▸ | GABRA5 | P31644 | 1/20 | 1.00 |
| ▸ | GABRA3 | P34903 | 1/20 | 1.00 |
| ▸ | GABRA2 | P47869 | 1/20 | 1.00 |
| ▸ | GABRB2 | P47870 | 1/20 | 1.00 |
| ▸ | GABRA4 | P48169 | 1/20 | 1.00 |
| ▸ | GABRE | P78334 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicuculline SCHEMBL28213750 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19CYP2D6TSHR | |
| Bicuculline SCHEMBL29652597 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19CYP2D6TSHR | |
| Bicuculline SCHEMBL29617593 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19CYP2D6TSHR | |
| Bicuculline SCHEMBL29390611 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19CYP2D6TSHR | |
| Bicuculline SCHEMBL5481014 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19CYP2D6TSHR | |
| Bicuculline SCHEMBL5783586 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19CYP2D6TSHR | |
| Bicuculline SCHEMBL8222 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19CYP2D6TSHR | |
| Bicuculline SCHEMBL29366341 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19CYP2D6TSHR | |
| Bicuculline SCHEMBL16320040 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19CYP2D6TSHR | |
| Bicuculline SCHEMBL2532354 | 0.99 | CYP3A4 (0.98) | CYP3A4CYP2C9CYP2C19CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023219526-A1 | MULTITARGET ANTIVIRAL DIETARY SUPPLEMENT | PROKIN MILAN (RS) | 2023-11-16 | — | — | WO | claimed |
| US-20260103736-A1 | Methods Of Improving Production Of Morphinan Alkaloids And Derivatives | ANTHEIA INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12497638-B2 | Methods of producing epimerases and benzylisoquinoline alkaloids | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-12-16 | — | — | US | disclosed |
| EP-4594342-A2 | METHODS OF IMPROVING PRODUCTION OF MORPHINAN ALKALOIDS AND DERIVATIVES | Antheia, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| EP-3221461-B1 | NOSCAPINOID-PRODUCING MICROBES AND METHODS OF MAKING AND USING THE SAME | UNIV LELAND STANFORD JUNIOR (US) | 2025-01-01 | — | — | EP | disclosed |
| US-20240218408-A1 | Methods of Producing Epimerases and Benzylisoquinoline Alkaloids | HERCULES CAPITAL, INC., AS AGENT | 2024-07-04 | — | — | US | disclosed |
| WO-2024073755-A2 | METHODS OF IMPROVING PRODUCTION OF MORPHINAN ALKALOIDS AND DERIVATIVES | ANTHEIA, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| US-20240102061-A1 | METHODS OF IMPROVING PRODUCTION OF MORPHINAN ALKALOIDS AND DERIVATIVES | HERCULES CAPITAL, INC., AS AGENT | 2024-03-28 | — | — | US | disclosed |
| US-11859225-B2 | Methods of producing epimerases and benzylisoquinoline alkaloids | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| WO-2023219526-A1 | MULTITARGET ANTIVIRAL DIETARY SUPPLEMENT | PROKIN MILAN (RS) | 2023-11-16 | — | — | WO | disclosed |
| US-5298220-A | Forming a coating of a solution containing anioic and cationic dyes and water insoluble organonitrogen compound, drying | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1994-03-29 | — | — | US | disclosed |
| US-5196164-A | During addition polymerization, wall coating of anionic dye and cationic dye and organonitrogen compound | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1993-03-23 | — | — | US | disclosed |
| CN-1040206-A | Prevent to form the method for polymer scale formation | SHINETSU CHEMICAL CO (JP) | 1990-03-07 | — | — | CN | disclosed |
| EP-0355575-A2 | Method of preventing polymer scale formation | Shin-Etsu Chemical Co., Ltd. (JP) | 1990-02-28 | — | — | EP | disclosed |
| CN-1006386-B | PROCESS FOR PRODUCTION OF VINYL CHLORIDE POLYMER | SHINETSU CHEM IND CO (JP) | 1990-01-10 | — | — | CN | disclosed |
| EP-0172427-B1 | PROCESS FOR PRODUCTION OF VINYL CHLORIDE POLYMER | Shin-Etsu Chemical Co., Ltd. (JP) | 1989-07-05 | — | — | EP | disclosed |
| US-4758639-A | Process for production of vinyl polymer | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1988-07-19 | — | — | US | disclosed |
| US-4757124-A | Suspension or emulsion polymerizing vinyl chloride monomer or mixture of vinyl chloride with vinyl monomer copolymerizable therewith in reactor with walls coated with antiscaling compound containing dye or pigments | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1988-07-12 | — | — | US | disclosed |
| CN-85107531-A | Process for producing vinyl chloride polymer | — | 1987-01-21 | — | — | CN | disclosed |
| EP-0172427-A2 | Process for production of vinyl chloride polymer | Shin-Etsu Chemical Co., Ltd. (JP) | 1986-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260103736-A1 | Methods Of Improving Production Of Morphinan Alkaloids And Derivatives | OPRK1, OPRM1, OPRD1 | CYP3A4 13/4885CYP2C9 27/4885CYP2C19 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.